1) Leasing and Demand Trends - Alexandria Real Estate Equities reported solid leasing activity in Q3 2026, with over 1.2 million square feet leased, marking the highest volume in the last seven quarters. - The weighted average lease term was approximately 11 years, with 74% of leasing attributed to existing tenants. - Public biotech leasing remained muted, contributing only 1.1% of total leasing volume, but there are expectations for improved leasing in Q4 with a projected 1.25 million square feet. - The company has a strong tenant base, with 57% of annual rental revenue coming from investment-grade or publicly traded large-cap tenants.

2) Financial Performance and Guidance - FFO per share diluted as adjusted was $1.54 for Q3 2026, reaffirming the midpoint of the 2026 guidance at $6.40 with a tighter range of plus or minus $0.02. - Same-property net operating income (NOI) declined by 6.7%, primarily due to lower occupancy levels, but there was an improvement compared to the previous quarter. - The company expects to meet its leverage target of 5.6x to 6.2x by year-end 2026, with a strong balance sheet and significant liquidity of $4.6 billion.

3) Development and Capital Plans - Alexandria has made significant progress on its capital plan, completing $1.7 billion in capital since June 30, including a $1 billion issuance of junior subordinated notes. - The company is focused on reducing noncore assets, with a 40% reduction in non-income-producing assets as a percentage of gross assets. - Development and redevelopment projects delivered 529,000 square feet during the quarter, generating an additional $40 million in annual NOI.

4) Market Challenges and Tenant Dynamics - The life science real estate market faces challenges, particularly with public biotech, which has seen valuations below historical averages. - There is an expectation of temporary pressure on occupancy in the first half of 2027 due to 1.4 million square feet of lease expirations, with potential downtime ranging from 9 to 24 months. - The company is actively negotiating with tenants for upcoming expirations, with 60% of the 1.37 million square feet of lease rolls currently engaged in discussions.

5) Outlook and Investor Considerations - Alexandria plans to provide more detailed guidance for 2027 at the upcoming Investor Day on December 2, 2026. - The company is focused on maintaining a strong balance sheet while navigating the current market conditions and tenant dynamics. - There is a need for continued strong leasing activity to improve occupancy and same-store NOI growth in 2028.

Bottom line: Alexandria Real Estate Equities is navigating a challenging market with solid leasing performance and a strong financial position. While facing headwinds in the public biotech sector and upcoming lease expirations, the company is well-positioned to capitalize on its high-quality tenant base and strategic capital plans, making it a potentially attractive investment for shareholders.